Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $238.00 USD
Change Today -1.36 / -0.57%
Volume 1.4M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Mexico
Frankfurt
As of 8:04 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International Mulls Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) is seeking acquisitions.

Valeant Pharmaceuticals International, Inc. - Shareholder/Analyst Call

Annual Meeting of Shareholders

Valeant Pharmaceuticals International, Inc. Announces Management Changes

On April 29, 2015, Valeant Pharmaceuticals International, Inc. announced that Howard B. Schiller intends to resign as Executive Vice President and Chief Financial Officer, effective at such time that his successor is appointed. Mr. Schiller will continue to serve on the company's Board of Directors and, with the Board's continued recommendation of Mr. Schiller as a nominee for re-election to the Board, Mr. Schiller intends to stand for re-election at the company's 2015 annual shareholder meeting. The company also announced that Anne C. Whitaker, former President and Chief Executive Officer of Synta Pharmaceuticals, will join Valeant's Executive Management Team as Executive Vice President and Company Group Chairman.

Valeant Pharmaceuticals International, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second Quarter of 2015, Full Year of 2015 and 2016

Valeant Pharmaceuticals International, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $2,190.9 million compared to $1,886.2 million for the same period a year ago. Operating income was $543.4 million compared to $356.6 million a year ago. Income before provision for income taxes was $155.4 million compared to $4.8 million a year ago. Net profit was $74.5 million compared to net loss was $20.3 million a year ago. Net profit attributable to the company was $73.7 million or $0.22 per basic and diluted share compared to net loss attributable to the company was $22.6 million or $0.07 per basic and diluted share a year ago. Adjusted net income attributable to the company was $809.3 million compared to $599.7 million a year ago. Diluted cash earnings per share were $2.36 compared to $1.76 per share a year ago. Non GAAP basis, operating income was $486.5 million compared to $493.8 million a year ago. Income before provision for income taxes was $673.0 million compared to $612.3 million a year ago. Total adjustments to net income attributable to the company $735.6 million or $2.14 per diluted share compared to $622.3 million or $1.82 per diluted share last year. Net cash provided by operating activities was $491.1 million compared with $484.3 million a year ago. Adjusted cash flow from operations was $708.1 million compared to $636.3 million a year ago. For the second quarter of 2015, the company expects total revenue of $2.45 billion to $2.55 billion, cash EPS $2.40 to $2.50 per share. For the year of 2015, the company expects increasing total revenue to $10.4 billion to $10.6 billion up from $9.2 billion to $9.3 billion, expect salix revenue of $1.0 billion in 2015, increasing Cash EPS to $10.90 to $11.20 per share up from $10.10 to $10.40, expect Same Store Sales Organic Growth of 10% for the second through fourth quarters of 2015. For the year of 2016, the company expects Accretion from Salix acquisition will be greater than 20% in 2016 and EBITDA expected to exceed $7.5 billion in 2016.

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. Announces RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

April 24, 2015 Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic non-cancer pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $238.00 USD -1.36

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $305.71 USD -3.45
Astellas Pharma Inc ¥1,819 JPY -15.50
Bristol-Myers Squibb Co $65.80 USD -0.68
Mylan NV $72.28 USD -1.04
Sun Pharmaceutical Industries Ltd 860.75 INR -16.90
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 81.5x
Price/Sales 9.4x
Price/Book 12.7x
Price/Cash Flow 32.9x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.